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Abstract
Background: Obesity and vaginal microbiome (VMB) dysbiosis are each risk factors for adverse reproductive and
oncological health outcomes in women. Here, we investigated the relationship between obesity, vaginal bacterial
composition, local inflammation and bariatric surgery.
Methods: Vaginal bacterial composition assessed by high-throughput sequencing of bacterial 16S rRNA genes and
local cytokine levels measured using a multiplexed Magnetic Luminex Screening Assay were compared between 67
obese and 42 non-obese women. We further assessed temporal changes in the microbiota and cytokines in a
subset of 27 women who underwent bariatric surgery.
Results: The bacterial component of the vaginal microbiota in obese women was characterised by a lower
prevalence of a Lactobacillus-dominant VMB and higher prevalence of a high diversity (Lactobacillus spp., and
Gardnerella- spp. depleted) VMB, compared with non-obese subjects (p<0.001). Obese women had higher relative
abundance of Dialister species (p<0.001), Anaerococcus vaginalis (p=0.021), and Prevotella timonensis (p=0.020) and
decreased relative abundance of Lactobacillus crispatus (p=0.014). Local vaginal IL-1β, IL-4, IL-6, IL-8, IFNγ, MIP-1α
and TNFα levels were all higher among obese women, however, only IL-1β and IL-8 correlated with VMB species
diversity. In a subset of obese women undergoing bariatric surgery, there were no significant overall differences in
VMB following surgery; however, 75% of these women remained obese at 6 months. Prior to surgery, there was no
relationship between body mass index (BMI) and VMB structure; however, post-surgery women with a Lactobacillus-
dominant VMB had a significantly lower BMI than those with a high diversity VMB.
Conclusions: Obese women have a significantly different vaginal microbiota composition with increased levels of
local inflammation compared to non-obese women. Bariatric surgery does not change the VMB; however, those
with the greatest weight loss 6-month post-surgery are most likely to have a Lactobacillus-dominant VMB.
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Background
Obesity has become a worldwide problem, with projec-
tions of 1 in 5 women being obese and 1 in 10 morbidly
obese by 2025 [1]. The gynaecological complications of
obesity include menstrual disorders [2, 3], anovulation
[4], polycystic ovarian syndrome [5, 6], infertility [7–9],
early pregnancy loss [10–12], preterm birth [13], obstet-
ric complications [13, 14] and increased risk for gynae-
cological malignancies (endometrial and ovarian) [15–
18]. The mechanism by which obesity promotes several
of these outcomes is not fully understood.
There is growing recognition that microbiota (i.e. the
assemblage of microorganisms found at a specific envir-
onment [19]) and their functions influence disease
pathophysiology [20–22]. Shifts in microbiota compos-
ition at mucosal surfaces can lead to pathobiont over-
growth and activation of innate immune responses that
in turn are modified by microbial products such as
short-chain fatty acids, lipids, and bioamines [23–26].
The vaginal microbiota is commonly dominated by
Lactobacillus spp. [27, 28], which offer protection
against colonisation of pathogenic bacteria through pro-
duction of lactic acid, lowering of vaginal pH, produc-
tion of antimicrobial compounds and modulation of
both the immunological and physical properties of cervi-
covaginal mucosa [29, 30]. High-throughput sequencing
approaches have aided characterisation of the vaginal
microbiota in health and disease states, leading to a bet-
ter understanding of the factors which affect vaginal
community composition including age and ethnicity
[31], menstrual cycle phase [32], oestrogen levels and
menopause status [33], intercourse [34], pregnancy [35,
36] and hygiene practices [37].
Bacterial vaginosis (BV), characterised by a shift from
Lactobacillus spp. dominance towards high relative
abundance of anaerobes, has long been associated with a
range of adverse outcomes [38]. Molecular-based char-
acterisation of vaginal bacteria composition has extended
these findings to permit identification of specific taxa
that modify risk of preterm birth [39–42] and preterm
premature rupture of membranes [43], sexually trans-
mitted infections [44], human papilloma virus and cer-
vical disease [45–47].
Obesity and specific vaginal microbiome (VMB) com-
positions are each risk factors for adverse reproductive
and oncological health outcomes in women, but there is
limited evidence describing the relationship between va-
ginal microbiota composition and obesity and the impact
that body weight may have on local inflammation, im-
mune response and health outcomes. Brookheart and
colleagues found that overweight and obese women have
higher Nugent scores and a greater occurrence of BV
[48]. Conversely using data from the US National Health
and Nutrition Examination Survey 2001-2004, Koumans
and co-workers concluded that body mass index (BMI)
was not an independent risk factor for BV [49]. Two Ko-
rean studies have examined the relationship between
VMB, assessed by metataxanomic analysis, and obesity.
Oh and colleagues found that obesity associates with
cervical microbiota dominated by Lactobacillus iners
[50]. Si and co-workers reported that discordant twin
obesity associated with increased bacterial diversity and
prevalence of Prevotella [51].
In this study, we investigated how obesity, defined as
BMI ≥30 kg/m2, associates with bacterial structure and
composition of the vaginal microbiome compared to
non-obese women and local inflammation. In a second-
ary analysis, we investigated the effects of bariatric
surgery on vaginal bacterial diversity and local
inflammation.
Results
A total of 109 women were prospectively recruited into
this study, 67 were non-obese and 42 were obese (Table
1). Non-obese women were more likely to be nulliparous
(p<0.001), non-diabetic (p=0.001), using contraception
(p=0.016) and Caucasian (p=0.024) compared to obese
women. There was no difference in mean age (p=0.083),
smoking (p=0.128) or menopause status (p=0.233) (Fish-
er’s exact test). No differences were found between re-
cent antibiotic use (p=0.258) or time since last sexual
intercourse prior to sample collection (p=0.070) (data
not shown).
A subset of twenty-seven of the 109 recruited
women were scheduled for bariatric surgery and were
sampled at baseline (n=27), 3 months (n=22) and 6
months (n=19) post-surgery. Cohort characteristics
are shown in Supplementary Table 1. The mean age
was 48 years (SD 8.91, range 28-65 years), and the
majority of women in the bariatric surgery cohort
were Caucasian (18/27, 66.7%), premenopausal (17/27,
63.0%) and only one postmenopausal participant used
HRT. One third of the cohort were diabetic (8/27,
29.6%), and half of the women who were diabetic re-
quired insulin. We found that 44% of the cohort was
insulin resistant at baseline.
In the 16S rRNA gene sequencing analysis, a total of 3,
045,614 reads were captured from 166 samples (109
baseline, 57 longitudinal samples) with an average num-
ber of reads per sample of 18,021. To avoid sequencing
bias, operational taxonomic units (OTUs) were ran-
domly sub-sampled to the lowest common read count of
1885 with coverage of greater than 95% (Good’s cover-
age index) being maintained for all samples. A total of
265 taxa were detected in the study cohort microbiota
after the removal of singletons and rare OTUs. Rare
OTUs were defined as those present at less than 10
counts within the entire cohort, and along with
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Table 1 Patient characteristics of the whole cohort at baseline sample collection (n=109) according to obesity status
Characteristics Non-obese (n=67) Obese (n=42) Total (n=109) p valuea
Age (years) 0.083
Mean (SD, range) 44 (11.79, 20-75) 46 (11.26, 28-72) 44 (11.79, 20-75)
Ethnicity, n/N (%) 0.024
Caucasian 48/67 (71.6) 22/42 (52.4) 70/109 (64.2)
Asian 3/67 (4.5) 5/42 (11.9) 8/109 (7.3)
Black 12/67 (17.9) 15/42 (35.7) 27/109 (24.8)
Other 4/67 (6.0) 0/42 (0) 4/109 (3.7)
Parity, n/N (%) <0.001
Nulliparous 44/67 (65.7) 7/42 (16.7) 51/109 (46.8)
Parous 23/67 (34.3) 35/42 (83.3) 58/109 (53.2)
Smoking status, n/N (%) 0.128
Current smoker 11/67 (16.4) 2/42 (4.8) 13/109 (11.9)
Non-smoker 56/67 (83.6) 40/42 (95.2) 96/109 (88.1)
HVS results n/N (%) 0.062
Normal 46/67 (68.7) 36/42 (85.7) 82/109 (75.2)
Abnormal 15/67 (22.4) 6/42 (14.3) 21/109 (19.3)
Unknown 6/67 (8.9) 0/42 (0) 6/109 (5.5)
Abnormal HVS results, n/N (%) 0.076
Bacterial vaginosis 3/15 (20.0) 1/6 (16.7) 4/21 (19.0)
E. coli 1/15 (6.7) 0/6 (0) 1/21 (4.8)
S. aureus 1/15 (6.7) 0/6 (0) 1/21 (4.8)
Group B streptococcus (S. agalactiae) 2/15 (13.3) 3/6 (50.0) 5/21 (23.8)
Yeast 0/15 (0) 1/6 (16.7) 1/21 (4.8)
Mixed coliforms 0/15 (0) 1/6 (16.6) 1/21 (4.8)
Unknown 8/15 (53.3) 0/6 (0) 8/21 (38.0)
Menopause status, n/N (%) 0.233
Premenopausal 50/67 (74.6) 26/42 (61.9) 76/109 (70.0)
Postmenopausal 17/67 (25.4) 16/42 (38.1) 33/109 (30.0)
Phase of menstrual cycle (PrMP), n/N (%) 0.115
Luteal 24/50 (48.0) 7/26 (26.9) 31/76 (40.8)
Follicular 15/50 (30.0) 8/26 (30.8) 23/76 (30.3)
Ovulation 0/50 (0) 1/26 (3.8) 1/76 (1.3)
Unknown 11/50 (22.0) 10/26 (38.5) 21/76 (27.6)
Use of contraception (PrMP), n/N (%) 0.016
Nil 27/50 (54.0) 20/26 (77.0) 47/76 (61.9)
Condoms 5/50 (10.0) 0/26 (0) 5/76 (6.6)
COCP 12/50 (24.0) 1/26 (3.8) 13/76 (17.1)
POP 1/50 (2.0) 0/26 (0) 1/76 (1.3)
Copper IUD 0/50 (0) 0/26 (0) 0/76 (0)
Mirena IUS 3/50 (6.0) 5/26 (19.2) 8/76 (10.5)
Vaginal ring 0/50 (0) 0/26 (0) 0/76 (0)
Contraceptive implant 2/50 (4.0) 0/26 (0) 2/76 (2.6)
Contraceptive injection 0/50 (0) 0/26 (0) 0/76 (0)
Use of HRT (PoMP), n/N (%) 0.175
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singletons, were included in the final analysis to main-
tain consistent read counts across all samples.
Vaginal microbiota composition and local cytokine
expression according to obesity, diabetes and insulin
resistance status
Ward hierarchical clustering analysis of genera-level data
identified three major groups, on the basis of relative
bacterial abundance: (i) Lactobacillus-dominant—char-
acterised by high relative abundance of Lactobacillus
spp., (ii) Gardnerella-dominant—characterised by high
relative abundance of Gardnerella spp. and low relative
abundance of Lactobacillus species and (iii) high diver-
sity VMB—characterised by low relative abundance of
each of Lactobacillus and Gardnerella species, and in-
creased bacterial diversity (Fig. 1a). Across the whole co-
hort, the prevalence of Lactobacillus-dominant and high
diversity VMB groups were significantly different (Fig.
1b). The frequency of the bacterial groups within patient
groups subcategorised on the basis of obesity status, dia-
betes and insulin resistance status is presented in Table
2. Prevalence of the high diversity VMB was significantly
greater in obese women (obese; 18/42 (42.8%) compared
to non-obese; 10/67 (14.9%), p=0.002) whilst the preva-
lence of Lactobacillus-dominant VMB was significantly
lower (Table 2). There was no difference in the preva-
lence of Gardnerella-dominant VMB between obese and
non-obese women. There were overall no significant
associations between the three major vaginal bacterial
groups and diabetes (Table 2) or where diabetic status
was subcategorised into obese or non-obese women
(Supplementary Table 2).
When women who had used antibiotics within 2
weeks of sample collection or had sexual intercourse
within 48 h of sample collection were excluded, the
prevalence of both the high diversity and Lactobacillus-
dominant VMB remained significantly different in obese
women in both categories (excluding intercourse, p=
0.001; excluding recent antibiotic use, p=0.003) (Supple-
mentary Table 3). When pre- and post-menopausal
women were analysed separately, premenopausal obese
women had a significantly higher prevalence of a high
diversity VMB (p=0.001), even when oral contraceptive
(OCP) users were excluded (p=0.003). There was a sig-
nificant difference in the prevalence of each genus ac-
cording to subcategories of normal weight, overweight
and obese women (p<0.001) (Supplementary Table 3).
Consistent with an increased prevalence of high diver-
sity VMB (Fig. 2a), increased richness (number of spe-
cies observed) and alpha diversity was observed in obese
women (diversity, p= 0.006) (Fig. 2b, c, Supplementary
Table 4). The vaginal microbiota of obese women was
characterised by a greater mean proportion of anaerobic
bacterial species, specifically unclassified Dialister spp.
(unclassified) (p<0.001), Anaerococcus vaginalis (p=
0.021) and Prevotella timonensis (p=0.020) (Fig. 2d).
Table 1 Patient characteristics of the whole cohort at baseline sample collection (n=109) according to obesity status (Continued)
Characteristics Non-obese (n=67) Obese (n=42) Total (n=109) p valuea
Yes 5/17 (29.4) 1/16 (6.2) 6/33 (18.2)
No 12/17 (70.6) 15/16 (93.8) 27/33 (81.8)
Diabetes status, n/N (%) 0.001
Non-diabetic 65/67 (97.0) 32/42 (76.2) 97/109 (89.0)
Diabetic 2/67 (3.0) 10/42 (23.8) 12/109 (11.0)
Diabetic treatment, n/N (%) 0.212
Diet control only 1/2 (50.0) 3/10 (30.0) 4/12 (33.3)
Metformin alone 0/2 (0) 3/10 (30.0) 3/12 (25.0)
Metformin combined 2nd diabetic medication 0/2 (0) 0/10 (0) 0/12 (0)
Other oral antiglycaemic medication 1/2 (50.0) 0/10 (0) 1/12 (8.4)
Insulin (alone or with oral medication) 0/2 (0) 4/10 (40.0) 4/12 (33.3)
HOMA-IRb, n/N (%) 0.136
Insulin resistant 2/67 (3.0) 5/42 (11.9) 7/109 (6.4)
Non-insulin resistant 5/67 (7.5) 5/42 (11.9) 10/109 (9.2)
Unknown insulin resistance status 60/67 (89.5) 32/42 (76.2) 92/109 (84.4)
BMI body mass index, COCP combined oral contraceptive pill, E. coli Escherichia coli, HOMA-IR homeostatic model of assessment-insulin resistance, HVS high
vaginal swab, IUD intrauterine device, IUS intrauterine system, PoMP postmenopausal, POP progesterone-only pill, PrMP premenopausal, S. aureus Staphylococcus
aureus, SD standard deviation
aCalculated using Fisher’s exact test. A p value of less than 0.05 demonstrates a significant difference in the distribution of the demographic of interest (e.g.
ethnicity), according to obesity status
bHOMA-IR was calculated according to the formula: fasting insulin (μU/L) multiplied by fasting glucose (nmol/L)/22.5. The 2nd tertile was used as the cut-off to
determine insulin resistance status. Insulin resistance cut-off value, 2.98
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To identify vaginal microbiota biomarkers specifically
associated with obesity, we performed linear discrimin-
ant analysis (LDA) effect size (LefSe) modelling on the
16S rRNA gene sequence data collected from baseline
samples (Supplementary Figure 1). Vaginal microbiota of
obese women was enriched with members of Bacteroi-
dales and Clostridiales, the Prevotella genus and the
phylum Actinobacteria. Conversely, non-obese women
were found to have enriched levels of Lactobacillales as-
sociated OTUs.
Obese women had significantly increased expression
of pro-inflammatory cytokines IL-1β, IL-6, IL-8, MIP-1α,
IFNγ and TNFα compared to non-obese women (Fig.
3a, Supplementary Table 5). The anti-inflammatory
cytokine IL-4 showed increased expression among obese
women. As bacterial diversity increased among obese
women (depicted using non-parametric Shannon Index),
the expression of IL-1β and IL-8 but not the other cyto-
kines, increased (Fig. 3b).
Metabolic and vaginal microbiota compositional changes
after bariatric surgery
At 6 months post bariatric surgery, the mean body
weight of participants decreased on average by 19.2%,
weight loss was similar for pre- and post-menopausal
women (Supplementary Table 6). This change translated
into a mean reduction of BMI of 10.3 (range 3.9 to 31.3)
from a pre-surgery mean of 47.4 to a mean of 35.8 (6
Fig. 1 a Hierarchical clustering analysis of genera taxonomic level data generates three distinct groups consisting of (i) Lactobacillus-dominant
(characterised by high relative abundance of Lactobacillus spp.), (ii) Gardnerella-dominant (characterised by high relative abundance of Gardnerella
spp. and low relative abundance of Lactobacillus spp.) and (iii) high diversity vaginal microbiome (VMB)—characterised by low relative abundance
of each of Lactobacillus and Gardnerella species, and increased bacterial diversity. Heatmap created from all samples collected (n=166), using
Ward linkage with the fifty most commonly identified microbial genera shown. Cohort characteristics including BMI category, menopause status,
ethnicity, contraceptive or hormone replacement therapy (HRT) use and diabetic status are also shown below the heatmap
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months post-surgery). Five of 19 women moved from
the obese category to the overweight category. The
remaining 14 women persisted within the obese
category.
In the subset of obese women undergoing bariatric
surgery, there were no significant overall differences in
VMB following surgery (Fig. 4a, Supplementary Figure
3). Neither were changes observed following bariatric
surgery according to menopause status, diabetes or insu-
lin resistance status (Table 3). Prior to surgery, there
was no relationship between BMI and VMB structure;
however, post-surgery women with Lactobacillus-domin-
ant VMB had a significantly lower BMI than those with
a high diversity VMB (Fig. 4b). This difference princi-
pally applied to pre-menopausal women (Fig. 4c). Local
cervicovaginal cytokine levels in the bariatric surgery co-
hort at baseline sampling (n=27) and 6 months post-
surgery (n=21) did not show any significant changes
(Supplementary Figure 2).
Oestradiol levels and sex hormone-binding globulin
(SHBG) levels were measured in a subset of 10 bariatric
surgery patients at baseline and 6 months post-surgery
(Supplementary Table 6). There were no overall differ-
ences in serum oestradiol levels in women pre- and
post-surgery. There was no relationship between
oestradiol levels and magnitude of weight loss 6 months
post-surgery. Fasting glucose and insulin serum levels
were also measured and HOMA-IR (insulin resistance
index) was calculated. No associations were seen be-
tween oestradiol levels and SHBG levels or HOMA-IR
and VMB group.
As oestrogen levels vary during the menstrual cycle
and can be affected by exogenous sources of oestrogen
such as OCP and hormone replacement therapy (HRT),
we performed an analysis to include only postmeno-
pausal women that were not taking HRT (Supplemen-
tary Table 6). There was no significant difference in the
mean oestradiol levels (mean at baseline sampling was
55.0 pmol/L (range 37.0-82.0 pmol/L) and mean 6
months post-surgery was 37.0 pmol/L (range 37.0-37.0
pmol/L), (p=0.371)). SHBG levels increased in the total
cohort after 6 months by 39.3% (p=0.008).
Discussion
In the UK, two thirds of the female population is either
overweight (30%), obese (27%) or morbidly obese (4%)
[52]. Obesity has been associated with a multitude of ad-
verse health outcomes in women [2, 4, 5, 12, 18], and al-
though the mechanisms leading to these complications
of obesity in women remain unclear, the vaginal micro-
biota composition may be important.
In our cohort, we found three VMB groups at genus
level. Approximately half of the vaginal samples were
categorised as Lactobacillus-dominant VMB, whilst the
Table 2 Prevalence of genus group present according to obesity status, diabetes and insulin resistance status for the whole cohort










Non-obese (BMI <30.0 kg/m2) 41/67 (61.2) 16/67 (23.9) 10/67 (14.9) 67/67 (100)
Obese (≥30.0 kg/m2) 12/42 (28.6) 12/42 (28.6) 18/42 (42.8) 42/42 (100)
Total 53/109 (48.6) 28/109 (25.7) 28/109 (25.7) 109/109 (100)
p valuea 0.002
Diabetes status
Non-diabetic 49/97 (50.5) 25/97 (25.8) 23/97 (23.7) 97/97 (100)
Diabetic 4/12 (33.3) 3/12 (25.0) 5/12 (41.7) 12/12 (100)
Total 53/109 (48.6) 28/109 (25.7) 28/109 (25.7) 109/109 (100)
P value 0.451
Insulin resistance statusb
Non-insulin resistant 4/10 (40.0) 2/10 (20.0) 4/10 (40.0) 10/10 (100)
Insulin resistant 2/7 (28.6) 2/7 (28.6) 3/7 (42.9) 7/7 (100)
Total 6/17 (35.3) 4/17 (23.5) 7/17 (41.2) 17/17 (100)
p value 1.000
BMI body mass index
aA p value of less than 0.05 demonstrates a significant difference in the distribution of genus group present according to obesity, diabetic and insulin resistance
status. Fisher’s exact test employed as small numbers were present for each group (e.g. diabetic)
bWhere concomitant fasting serum samples were available, fasting glucose and fasting insulin levels were identified. Using these values, we were able to calculate
the HOMA-IR, according to the formula: the product of fasting insulin (μU/L) multiplied by fasting glucose (nmol/L) divided by 22.5. The 2nd tertile was used as
the cut-off to determine insulin resistance status. Insulin resistance cut-off value, 2.98
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remaining samples were categorised in equal proportion
as either Gardnerella-dominant (with a high relative
abundance of Gardnerella spp. and low relative abun-
dance of Lactobacillus spp.), or high diversity VMB (with
a low relative abundance of each of Lactobacillus and
Gardnerella spp., and increased bacterial diversity).
When these samples were analysed with respect to obes-
ity status, about 70% of obese women demonstrated a
Lactobacillus-dominant VMB. This proportion is con-
sistent with other reported studies. Brotman and col-
leagues showed that a Lactobacillus-dominant VMB is
found in 80% of premenopausal women, but only 55% of
postmenopausal women [53]. Our study represents a
mixture of pre- and post-menopausal women. In those
who were categorised as obese, 30% of women had a
Lactobacillus-dominant VMB. This prevalence is lower
than that found in non-obese postmenopausal women
[53]. Our study shows that obesity associates with vagi-
nal microbiota composition, with significantly higher va-
ginal bacterial species diversity and increased abundance
of Dialister, Prevotella and Anaerococcus among obese




Fig. 2 a The prevalence of the Lactobacillus-dominant genus group was lower in obese compared to non-obese women (p<0.001). b Number of
species observed (Sobs) increased with obesity (p=0.002). c Significantly increased microbial diversity was seen among obese women (p=0006). d
The vaginal microbiome of obese women was characterised at genus level by increased mean proportion (%) of Dialister, Prevotella and
Anaerococcus. Results at species level showed increased mean proportion (%) of Dialister (unclassified), Prevotella timonensis and Anaerococcus
vaginalis in obese women, and Lactobacillus crispatus dominated among non-obese women
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a
b
Fig. 3 (See legend on next page.)
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cohorts, have described vaginal microbiota composition
in relation to obesity in a non-pregnant population. The
first study reported that obese women had a greater
predominance of Lactobacillus iners compared to non-
obese women who were more likely to have a Lactoba-
cillus crispatus-dominant VMB [50]. However, this study
was limited to the analysis of interrelationships between
cervical Lactobacillus species only with non-Lactobacil-
lus members of the microbiota not considered. There-
fore, the generalisability of these findings are unclear
[50]. Our findings lead us to conclude an increased
prevalence of Dialister (unclassified), Prevotella timonen-
sis and Anaerococcus vaginalis in obese women, and
dominance of Lactobacillus crispatus among non-obese
women (Fig. 2d). The second study, by Si et al., reported
that obesity was associated with increased levels of Pre-
votella, and reduced Lactobacillus relative abundance
consistent with our data [51].
The vaginal microbiota composition is dynamic and
fluctuates throughout the life cycle with relative domin-
ance of the niche by Lactobacillus spp. mediated by
oestrogen-driven vaginal epithelium thickening and
glycogen deposition, which is used as a primary energy
source by lactic acid producing bacteria, encouraging a
Lactobacillus-dominant VMB [54]. Accordingly, pre-
puberty and post-menopause vaginal microbiota com-
position associates with reduced glycogen levels [55] and
a tendency towards a high diversity vaginal microbiota
[56, 57]. In our study, vaginal microbiota composition in
pre- and post-menopausal women was largely consistent
with the published literature. In peri- or post-
menopausal women with declining ovarian function,
peripheral adipose tissue becomes the major source of
production of unopposed circulating oestrogen by
aromatisation of adrenal androstenedione to excess en-
dogenous oestrogen [58–60]. In this group of women,
reduced systemic oestrogen levels cause a decrease in
glycogen deposition resulting in a vaginal epithelia that
resembles pre-puberty with a thinner mucus layer and
increased incidence of high diversity VMB [61, 62].
However, oestrogen levels are not higher in premeno-
pausal obese women compared to non-obese. Freeman
and co-workers found that premenopausal obese and
overweight women had significantly lower oestradiol
levels compared with non-obese women, independent of
age, race or smoking [63]. Reduced circulating
oestrogen concentrations are therefore a potential ex-
planation for the lower prevalence of Lactobacillus-
dominant VMB in obese women. It is also possible
that due to restrictions in mobility caused by morbid
obesity, female hygiene practices are affected. Local
skin irritation and breakdown caused by the presence
and rubbing of excess adipose tissue, together with
persistent moisture may alter the local vaginal micro-
biota composition. The impact of women’s sexual,
sanitary and hygiene practices such as douching on
the vaginal microbiota is still controversial [64, 65].
Sustained weight loss may be brought about by signifi-
cant lifestyle changes (diet and increased physical activ-
ity) or induced by bariatric surgery that can result in
improved metabolic health. It has previously been re-
ported that bariatric surgery can reduce cancer incidence
[66], improve sex hormone profiles [67], polycystic ovar-
ian syndrome symptoms [68], spontaneous and assisted
conception rates [69–72] and reduce obstetric complica-
tions such as gestational diabetes, pregnancy-induced
hypertension and macrosomia [73, 74]. Reversal or re-
duction in obesity brought about by bariatric surgery has
been shown to be accompanied by metabolic improve-
ment and reduction of alpha-diversity of the gut micro-
biota within 3 months post-operatively [75–77]. The
impact of bariatric surgery on the vaginal microbiome
has not however been previously assessed. In our study,
in the subset of obese women undergoing bariatric sur-
gery, there were no significant overall differences in
VMB following surgery; however, 75% of these women
remained in the obese range. Prior to surgery, there was
no relationship between BMI and VMB structure; how-
ever, post-surgery women with Lactobacillus-dominant
VMB had a significantly lower BMI than those with a
high diversity VMB. Significant weight loss following
bariatric surgery therefore associates with a tendency to-
wards an “optimal” VMB. We did not, however, find any
correlation between degree of weight loss and systemic
oestradiol or SHBG concentrations. Additionally, SHBG
increased in every woman at 6 months post-surgery
which would lead to lower bioavailable oestrogen. It is
therefore unlikely that any effect of bariatric surgery
upon the VMB is principally due to changes in systemic
oestradiol or SHBG concentrations.
(See figure on previous page.)
Fig. 3 Pro-inflammatory local vaginal cytokine expression is increased in obesity. a Expression levels (log10) of seven cytokines measured among
non-obese and obese women in the baseline cohort. Pro-inflammatory cytokines IL-1β, IL-8, IFNγ and MIP-1α all showed significantly increased
expression among obese women (p<0.001). Anti-inflammatory cytokine IL-4 also had increased significance in obese women (p<0.001). b
Expression of seven local cervicovaginal cytokine levels (log10) according to obesity status and species diversity (non-parametric Shannon indices).
As the diversity of vaginal bacterial species increases, there is a significant increase in expression of pro-inflammatory cytokines IL-1β and IL-8,
dependent on obesity status
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Fig. 4 a Differences in proportion of vaginal microbiota groups from baseline (day of surgery) to 6 months post-surgery in the bariatric cohort. b
The mean BMI of each of the three genus groups at baseline sampling and at 6 months post-surgery. There was a significant reduction in mean
BMI in Lactobacillus-dominant VMB samples at 6 months post bariatric surgery (p<0.001). c The mean BMI of each of the three genus groups at
baseline and 6 months post-surgery, according to menopause status. There was a significant reduction in mean BMI in the Lactobacillus-
dominant group in premenopausal (p=0.002) and postmenopausal women (p=0.009)
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Table 3 Prevalence of genus group present over serial sample collection timepoints in the total bariatric cohort and according to









Total bariatric surgery cohort
Baseline (day of surgery) (n=27) 10/27 (37.0) 5/27 (18.6) 12/27 (44.4) 27/27 (100)
3 months post-surgery (n=22) 7/22 (31.8) 6/22 (27.3) 9/22 (40.9) 22/22 (100)
6 months post-surgery (n=19) 10/19 (52.6) 2/19 (10.5) 7/19 (36.9) 19/19 (100)
Total (n=84) 31/84 (36.9) 16/84 (19.1) 37/84 (44.0) 84/84 (100)
p valuea 0.506
Pre-menopausal women only
Baseline (day of surgery) (n=17) 6/17 (35.3) 4/17 (23.5) 7/17 (41.2) 17/17 (100)
3 months post-surgery (n=15) 5/15 (33.3) 4/15 (26.7) 6/15 (40.0) 15/15 (100)
6 months post-surgery (n=14) 8/14 (57.1) 2/14 (14.3) 4/14 (28.6) 14/14 (100)
Total (n=58) 22/58 (37.9) 12/58 (20.7) 24/58 (41.4) 58/58 (100)
p value 0.572
Post-menopausal women only
Baseline (day of surgery) (n=10) 4/10 (40.0) 1/10 (10.0) 5/10 (50.0) 10/10 (100)
3 months post-surgery (n=7) 2/7 (28.6) 2/7 (28.6) 3/7 (42.8) 7/7 (100)
6 months post-surgery (n=5) 2/5 (40.0) 0/5 (0) 3/5 (60.0) 5/5 (100)
Total (n=26) 9/26 (34.6) 4/26 (15.4) 13/26 (50.0) 26/26 (100)
p value 0.999
Non-diabetic women only
Baseline (day of surgery) (n=19) 6/19 (31.6) 3/19 (15.8) 10/19 (52.6) 19/19 (100)
3 months post-surgery (n=16) 6/16 (37.5) 4/16 (25.0) 6/16 (37.5) 16/16 (100)
6 months post-surgery (n=14) 8/14 (57.1) 1/14 (7.2) 5/14 (35.7) 14/14 (100)
Total (n= 58) 21/58 (36.2) 9/58 (15.5) 28/58 (48.3) 58/58 (100)
p value 0.572
Diabetic women only
Baseline (day of surgery) (n=8) 4/8 (50.0) 2/8 (25.0) 2/8 (25.0) 8/8 (100)
3 months post-surgery (n=6) 1/6 (16.7) 2/6 (33.3) 3/6 (50.0) 6/6 (100)
6 months post-surgery (n=5) 2/5 (40.0) 1/5 (20.0) 2/5 (40.0) 5/5 (100)
Total (n=26) 10/26 (38.5) 7/26 (26.9) 9/26 (34.6) 26/26 (100)
p value** n/a
Women without insulin resistancec
Baseline (day of surgery) (n=4) 1/4 (25.0) 1/4 (25.0) 2/4 (50.0) 4/4 (100)
3 months post-surgery (n=2) 0/2 (0) 0/2 (0) 2/2 (100) 2/2 (100)
6 months post-surgery (n=7) 4/7 (57.1) 1/7 (14.3) 2/7 (28.6) 7/7 (100)
Total (n=13) 5/13 (38.5) 2/13 (15.4) 6/13 (46.1) 13/13 (100)
p value n/a
Women with insulin resistance
Baseline (day of surgery) (n=5) 2/5 (40.0) 1/5 (20.0) 2/5 (40.0) 5/5 (100)
3 months post-surgery (n=1) 0/1 (0) 0/1 (0) 1/1 (100) 1/1 (100)
6 months post-surgery (n=1) 1/1 (100) 0/1 (0) 0/1 (0) 1/1 (100)
Total (n=7) 3/7 (42.9) 1/7 (14.3) 3/7 (42.9) 7/7 (100)
p valueb n/a
aA p value of less than 0.05 demonstrates a significant difference between the proportion (%) of genus group present (Lactobacillus-dominant, Gardnerella-
dominant or high diversity VMB) over serial timepoints 0 to 6 months (McNemar’s Chi-square test)
bSample size too small to compute p value using McNemar’s Chi-square test
cWhere concomitant fasting serum samples were available, fasting glucose and fasting insulin levels were identified. Using these values, we were able to calculate
the HOMA-IR, according to the following formula: the product of fasting insulin (μU/L) multiplied by fasting glucose (nmol/L) divided by 22.5. The 2nd tertile was
used as the cut-off to determine insulin resistance status. Insulin resistance cut-off value: 2.98
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In this study, we further explored how obesity may
affect local inflammation and whether this is driven by
increased diversity in the VMB. Previous studies have re-
ported how a number of immune modulators in obesity
(i.e. adipose tissue macrophages, cytokines and adipo-
kines) can drive systemic inflammation [78, 79]. Other
studies have shown that genital tract infection lead to
changes in local immune factors that in turn have been
linked to preterm birth [80] and bacterial vaginosis per-
sistence [81]. Cervicovaginal cytokine levels (IL-1β, IL-6,
IL-8, TNFα, MIP-1α and IFNγ) were increased in our
obese population. This is in line with previous reports
suggesting that modulation of the VMB in pregnancy in-
creases local expression of each of these cytokines which
correlates with increasing species diversity [82]. In the
present study, however, there was an association be-
tween increasing bacterial species diversity and expres-
sion of only two pro-inflammatory cytokines IL-1β and
IL-8. This data leads us to conclude that, in obesity, fac-
tors other than the VMB act to modulate cervicovaginal
inflammation. We found no significant change in cervi-
covaginal cytokine levels following bariatric surgery, and
cytokine concentrations were not different between the
different genera groups. This finding again shows that
much of the local cervicovaginal inflammation associated
with obesity is unrelated to the vaginal microbiota.
Previous cross-sectional studies have highlighted that
vaginal microbiota composition may be affected by obes-
ity [50, 51]. A strength of the present study is the assess-
ment of the vaginal microbiota composition in obese
pre- and postmenopausal women separately, after exclu-
sion of OCP and HRT-users and after taking into ac-
count confounding variables and hormonal serum levels.
Furthermore, this is the first study to explore the tem-
poral changes in the vaginal microbiota in a cohort of
morbidly obese women undergoing surgically induced
weight loss.
Although this study is one of the largest cohorts asses-
sing the impact of obesity on the vaginal microbiota
composition in women undergoing bariatric surgery,
temporal data collected at each of the three timepoints
was only available for a small number of patients which
limits our ability to draw meaningful conclusions for
many comparisons of interest. Recruitment of much lar-
ger numbers would be practically difficult. Follow-up for
longer periods may show changes not revealed at 6
months, maximum weight loss is usually achieved 12-24
months after surgery [83, 84], although the majority of
women who undergo bariatric surgery regain between 5
and 10% of their pre-operative weight by 2-3 years [84].
Furthermore, although negative controls have been in-
cluded with each DNA extraction set, no amplicons
were identified, and these were not subsequently se-
quenced. Given that vaginal samples are not considered
to be of low biomass and we previously reported sequen-
cing data of negative controls in similar contemporan-
eous patient cohorts [43, 85], we do not expect this to
have led to spurious results. Consistent with this, we did
not observe any common kit or environmental contami-
nants as being prominent features of any of the patient
samples sequenced in this study.
Conclusions
Obesity was found to be associated with higher vaginal
microbiome diversity that may partly explain changes in
local inflammation. Other factors beyond the VMB (i.e.
endocrine) are likely to affect local inflammatory state.
Surgery-induced weight loss did not change the VMB
composition, although three quarters of the women
remained obese 6 months post-surgery. Those with the
greatest weight loss 6-month post-surgery were more
likely to have a Lactobacillus-dominant VMB. A health-
ier VMB following bariatric surgery-induced weight loss
may create a healthier local microenvironment to pro-
mote health, but since this does not associate with a re-
duction in local inflammation, other factors are likely to
be involved and require further investigation.
Materials and methods
Study population—inclusion and exclusion criteria
We prospectively recruited non-pregnant women at-
tending outpatient gynaecology and bariatric surgery
clinics at Imperial College NHS Healthcare Trust be-
tween 2013 and 2016. A subset of this population was
scheduled for bariatric surgery. Women were recruited
irrespective of age, menopause status, ethnicity, parity,
smoking, phase in menstrual cycle and contraception
use. Women who were HIV, hepatitis B or C positive,
had autoimmune disorders, or had a previous hysterec-
tomy were excluded. Ethical approval was obtained from
the National Research Ethics Service Committee
London—Fulham (approval number 13/LO/0126) and
the NHS West of Scotland Research Ethics Service Com-
mittee (WoSRES) (REC 14/WS/1098). All patients gave
informed consent.
Sample collection and processing
Cervicovaginal secretions were collected during the
clinic visit from the posterior vaginal fornix with a
BBLTM CultureSwabTM containing liquid Amies (Becton
Dickinson, Oxford, UK) using a sterile, disposable
speculum, without lubricant and immediately stored at
−80 °C. A second transport microbiology swab (Trans-
wab®) containing Amies gel medium was simultaneously
collected for cytokine analysis. In the subset population
of women planned for bariatric surgery (Gastric band,
Roux-en-Y Gastric Bypass or Vertical Sleeve Gastrec-
tomy), we collected serial vaginal swab samples on the
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day of surgery and at months 3 and 6 post-surgery (Sup-
plementary Figure 4). Serial fasting blood samples were
also collected on the day of surgery and at 6-month
follow-up with the aim to correlate changes in vaginal
microbiota to four serum markers known to be affected
by surgery-induced weight loss and hyperinsulinaemia
correction. Blood samples were centrifuged at 4472×g
for 10 min and serum collected for freezing and storage
in −80 °C.
A comprehensive interview and questionnaire were
used to obtain all relevant gynaecological, medical and
surgical history. Menopause status, type of contraception
or HRT use and menstrual cycle phase (follicular or lu-
teal) were documented. Ethnicity was self-reported as
Caucasian, Asian, Black or other.
Whole-genomic bacterial DNA was extracted from the
CultureSwabTM using a QiAmp Mini DNA kit (Qiagen,
Venlo, Netherlands) as described previously [36]. The
second swab for cytokine analysis was thawed on ice and
re-suspended in 350 μl phosphate-buffered saline solu-
tion with protease inhibitor (5 μl/ml; Sigma Aldrich).
The suspension was centrifuged at 402×g for 2 min, and
supernatant collected into a new 1.5 ml microcentrifuge
tube. This centrifugation step was repeated to remove
any remaining cellular debris. The cell-free supernatant
was stored in −80 °C. Negative control swabs (blank, de-
void of patient sample) were processed alongside each
DNA extraction set. No amplicons were observed fol-
lowing PCR and gel electrophoresis of the negative con-
trols, and these were not subsequently sequenced.
Illumina MiSeq sequencing of 16S rRNA gene amplicons
and data processing
The V1-V2 hypervariable regions of 16S rRNA genes
were amplified by PCR using a forward and reverse fu-
sion primer, described in detail in Supplementary
Methods S1. Bacterial profiling using a MiSeq platform
(Illumina, San Diego, CA, USA) was conducted at Re-
search and Testing Laboratory (Lubbock, TX, USA). The
16S rRNA gene sequence data was analysed with bio-
informatic software package Mothur [86] using the
MiSeq SOP Pipeline. Sequence reads were quality
checked and normalised to the lowest number of reads
(n=1855) and singleton operational taxonomic units
(OTUs); samples containing fewer than 10 reads were
excluded. OTU taxonomies (from Phylum to Genus)
were then determined using the RDP MultiClassifier
script to generate the RDP taxonomy. Taxonomy level
for species of the OTUs was determined using the
USEARCH algorithm with 16S rRNA gene sequences
from the cultured representatives from the RDP data-
base [87]. Rare OTUs were defined as those present at
less than 10 counts within the entire cohort. Alpha and
beta diversity indices were calculated from these datasets
with Mothur and R statistical package using the Vegan
package.
Serum biomarker and local vaginal cytokine analyses
Four serum markers including oestradiol (pmol/L), insu-
lin (mIU/L), glucose (mmol/L) and sex hormone-
binding globulin (SHBG, nmol/L) were quantified using
ELISA at the Imperial College Healthcare NHS Trust
North West London Pathology laboratory (Supplemen-
tary Methods S2).
Levels of interleukin (IL)-4, IL-6, IL-8, IL-1β, tumour
necrosis factor-alpha (TNFα), interferon-gamma (IFN-γ)
and macrophage inflammatory protein-1 alpha (MIP1α)
in cell-free cervicovaginal secretion supernatants were
determined using the Magnetic Luminex Screening
Assay multiplex kit (R&D Systems, Minneapolis, MN,
USA) on a MAGPIX Analyzer (Luminex® Corporation,
s-Hertogenbosch, Netherlands), as per manufacturer’s
instructions. Analytes were chosen based on evidence of
inflammatory markers specific to adiposity [88–90].
Statistical analyses
The population was categorised into two groups of
interest for the main analysis, non-obese (BMI <30kg/
m2) versus obese (BMI ≥30kg/m2). We performed fur-
ther supplementary analyses to assess results for differ-
ent obesity status subcategories and according to insulin
resistance and diabetic status. The homeostatic model
assessment for insulin resistance (HOMA-IR) was calcu-
lated by the following formula: the product of fasting in-
sulin (μU/L) multiplied by fasting glucose (nmol/L)
divided by 22.5 [91]. We used the 2nd tertile value of
HOMA-IR as the cut-off to determine insulin resistance
status (at 2.98). Differences in categorical clinical param-
eters between the two main groups of interest (non-
obese versus obese) were assessed using Fisher’s exact
test for each of the listed characteristics: age, ethnicity,
parity, smoking, menopause, menstrual cycle, use of
contraception, HRT use, diabetes status and treatment
and abnormal high vaginal swab (HVS) results.
Significant differences between vaginal microbiota at
genera taxonomic level were assessed using the Statis-
tical Analysis of Metagenomic Profiles (STAMP) soft-
ware package [92]. Dependent on genera hierarchical
clustering analysis, Lactobacillus spp. or Gardnerella
spp. abundance among selected phenotypic categories
was investigated by assigning each patient sample into
one of three groups (Lactobacillus-dominant, Gardner-
ella-dominant or high diversity VMB). Linear discrimin-
ant analysis (LDA) effect size (LEfSe) modelling was
used to identify biomarkers based on obesity status, ac-
cording to relative taxonomic abundance [93].
At genus taxonomic level, prevalence of each of the
three categories relating to Lactobacillus or Gardnerella
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presence were compared between the two phenotypic
categories (obese or non-obese) using Fisher’s exact test.
We performed further sub-analyses for different weight
categories, as well as by the presence of diabetes and/or
insulin resistance status. A sensitivity analysis assessed
whether the exclusion of women that had antibiotics less
than 2 weeks before sample collection or those disclos-
ing sexual intercourse within 48 h from sampling would
affect the results. We further analysed the results for
pre- and post-menopausal women separately and after
exclusion of those taking oral hormonal contraception
or hormone replacement therapy (HRT).
Expression levels of assayed cytokines were compared
according to obesity status, prevalence of each genus
group and diversity (non-parametric Shannon Index) at
baseline sampling using two-way ANOVA. Where data
fell outside the range of the standard curve for each ana-
lyte, either the minimal or maximal extrapolated or min-
imal or maximal value of the standard curve was used,
where appropriate. Analyses were performed using
Prism 8, p values <0.05 considered significant.
In the subset of women undergoing bariatric surgery,
changes in serum markers introduced by weight loss
were analysed. We further assessed the impact of surgi-
cally induced weight loss on the prevalence of each of
the three genus groups at baseline, month 3 and 6 using
McNemar’s Chi square test. We analysed the results for
the full cohort and separately for pre- and post-
menopausal women, and according to diabetic and insu-
lin resistance status. Transition in vaginal microbiota
across genus groups correlating with weight loss from
baseline sampling to 6 months post-surgery was ana-
lysed for the total bariatric cohort and pre- and post-
menopausal women separately. Cytokine and serum
marker expression levels were compared between base-
line sampling and 6 months after surgically induced
weight loss.
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